{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-186939","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.958855+00:00","generated_at":"2026-05-15T03:38:53.088583+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"OPKO Health Q1 revenue falls to $124.2M, net loss narrows; pipeline advances","bullets":["Consolidated revenue $124.2M vs $149.9M YoY; net loss $54.8M ($0.07/sh) from $67.6M ($0.10/sh).","Pharma revenue $38.0M (+9% YoY); Diagnostics $72.2M, down from $102.8M due to Labcorp oncology asset sale.","Operating loss improved to $51.0M from $67.2M; cash $341.9M; $92M of stock repurchased under $200M authorization.","Phase 1 trials started for MDX2301 (COVID-19 prevention) and MDX2003 (B-cell lymphoma); in vivo CAR-T platform advancing.","FY2026 guidance reaffirmed: total revenue $530-560M; total costs $725-750M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-186939","json":"https://secwatch.observer/filing/0001193125-26-186939.json","markdown":"https://secwatch.observer/filing/0001193125-26-186939.md","text":"https://secwatch.observer/filing/0001193125-26-186939.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000119312526186939/0001193125-26-186939-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000119312526186939/opk-20260428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:38:53.088583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f65e36055d5278ccfee8cdaad352cf564d14df38","claim":"OPKO HEALTH, INC. reported the three months ended March 31, 2026 results: revenue $124.2 million, net income $54.8 million, EPS $0.07 per share.","evidence_excerpt":"each is responsible for 50% of the program's development costs. First Quarter Financial Results • Consolidated: Consolidated total revenues for the first quarter of 2026 were $124.2 million compared with $149.9 million for the 2025 period, with the decrease principally resulting from the sale of certain BioReference assets in 2025. Operating loss for the first","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/944809/000119312526186939/0001193125-26-186939-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Revenue","value":"$124.2 million"},{"label":"Net income","value":"$54.8 million"},{"label":"EPS","value":"$0.07 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}